$-0.41 EPS Expected for PLx Pharma Inc. (PLXP)

July 14, 2018 - By Nellie Rakes

Analysts expect PLx Pharma Inc. (NASDAQ:PLXP) to report $-0.41 EPS on August, 9.They anticipate $0.13 EPS change or 24.07 % from last quarter’s $-0.54 EPS. After having $-0.40 EPS previously, PLx Pharma Inc.’s analysts see 2.50 % EPS growth. The stock decreased 2.47% or $0.1 during the last trading session, reaching $3.95. About 692 shares traded. PLx Pharma Inc. (NASDAQ:PLXP) has declined 26.38% since July 14, 2017 and is downtrending. It has underperformed by 38.95% the S&P500.

PLx Pharma Inc., a late-stage specialty pharmaceutical company, focuses on developing nonsteroidal anti-inflammatory drugs and other pharmaceutical agents. The company has market cap of $34.48 million. The Company’s lead product is Aspertec 325 mg, a novel formulation of aspirin that uses the PLxGuard delivery system to reduce acute gastrointestinal side effects while providing antiplatelet effectiveness for cardiovascular disease prevention. It currently has negative earnings. The company??s product pipeline also includes other oral nonsteroidal anti-inflammatory drugs using the PLxGuard delivery system, including PL1200 Ibuprofen 200 mg, a clinical-stage GI-safer ibuprofen product for pain and inflammation; and Aspertec 81 mg, a novel formulation of aspirin, which is in late-stage development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.